 SEATTLE, WA ACCESSWIRE August 12, 2021 Aptevo Therapeutics Inc. Aptevo or the Company NASDAQ:APVO, a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today reported its financial results and business highlights for the quarter ended June 30, 2021. Business Highlights Announced results from the Companys Phase 1 dose escalation trial evaluating lead ADAPTIR candidate, APVO436, for the treatment of acute myeloid leukemia and myelodysplastic syndromes AMLMDS. 